2. Analysis of incidence and mortality of stomach cancer in China from 2003 to 2007
Tumor 2012;32(2):109-114
Objective: To analyze the incidence and mortality of stomach cancer in China from 2003 to 2007. Methods: The registration data during 2003 to 2007 from 32 cities/ counties were used to estimate stomach cancer incidence and mortality and their changing trends in China. Results: The crude incidence rate of stomach cancer was 33.14/100 000 and the age-standardized rate (ASR) by world population was 23.09/100 000, ranked the second of all new cancer cases during 2003 to 2007 in China. A higher incidence rate was found in the males than in the females. In the same time period, the crude mortality rate of stomach cancer was 24.34/100 000, and the ASR by world population was 16.39/100 000, ranked the third of all cancer deaths, with a higher rate in the males than in the females. The age-specific incidence and mortality rates were increased with increasing age. The differences of ASR in the incidence and the mortality by world population among different regions were found as high as 16.3 and 19.1 folds in the males, and 17.5 and 27.0 folds in the females, respectively. Conclusion: The incidence and mortality of stomach cancer are still high in China from 2003 to 2007. There are substantial variations in the incidence and mortality rates of stomach cancer by age and region. Copyright © 2012 by TUMOR.
3.Clinical Study on Shenfukang Capsules for Renal Insufficiency
Guozhen CAI ; Xiaobin ZHONG ; Yufang YANG ; Xiaoqin ZOU ; Qiuping NONG ; Sisi LU ; Xueyan LIANG
China Pharmacy 2017;28(14):1934-1937
OBJECTIVE:To investigate the effects of Shenfukang capsules on clinical efficacy and renal function indexes of patients with renal insufficiency. METHODS:Totally 100 inpatients with renal insufficiency treated by Shenfukang cap-sules in the First Affiliated Hospital of Guangxi Medical University during Feb. to Mar. 2015 were analyzed retrospectively in respects of general information of patients,therapy plan,renal function indexs before and after treatment and clinical effica-cy. The relationship of clinical efficacy with age and duration was also analyzed. RESULTS:There were 33 cases of acute re-nal insufficiency and 67 cases of chronic renal insufficiency. The route of administration of Shenfukang capsules was oral ad-ministration(97 cases,97.00%),the main dosage was 6 capsule/d(36 cases,36.00%),and treatment duration were 0-<7 days(39 cases)and 7-<15 days(49 cases). After treatment,the average serum creatinine concentration was lower than be-fore treatment,while mean GFR and Ccr were higher than before treatment,with statistical significance(P<0.05). The total response rate was 72.00%,and response rate of patients with acute renal insufficiency was 87.88% and significantly higher than 64.18% of patients with chronic renal insufficiency,with statistical significance(P<0.05). Among patients with ≤60 years old,the total response rate of patients with acute renal insufficiency was significantly higher than that of patients with chronic renal insufficiency,with statistical significance(P<0.05);among patients elder than 60 years old,there was no statistical significance in therapeutic efficacy between acute renal insufficiency and chronic renal insufficiency(P>0.05);among patients with chronic renal insufficiency,the total response rate of patients elder than 60 years old was significantly better than that of patients with ≤60 years old,with statistical significance (P<0.05). With the extension of treatment duration,the total response rate of patients with acute renal insufficiency was on the rise,and that of patients with chron-ic renal insufficiency increased first and then decreased. No obvious ADR was found during treatment. CONCLUSIONS:Shenfu-kang capsules can improve renal function in patients with renal insufficiency,and has definite curative effect on acute and chronic renal insufficiency with good security. The clinical efficacy may be related to age and treatment course.
4.The Effects of Compound Tripterygium Hypoglaucun Hutch on Photoallergic Contact Dermatitis of Murine Model
Xiang NONG ; Li HE ; Ping WAN ; Yongli ZOU ; Ling LIU ; Jin GUO
Chinese Journal of Dermatology 2003;0(10):-
Objective To study the efficacy and mechanism of compound Tripterygium hypoglaucum Hutch (THH) on photoallergic contact dermatitis in mice. Methods The photoallergic animal model of BALB/c mice was established by using photosensitizer chlorpromazine and UVA irradiation. The therepeutic efficacy was determined by measuring the thickness and the weight of the swelling ear and the number of infiltrated mononuclear cells in the ear tissue. Immunohistochemical technique was used to detect the ICAM-1 expression on keratinocytes, fibroblasts and vascular endothelial cells. The serum level of INF-? was measured by ELISA. The tested animals were divided into 3 groups: compound THH, THH alone and normal saline. Results The difference of the thickness of left ear before and after challenge, the differences of the thickness and the weight of ear tissue, the difference of the number of infiltrated mononuclear cells of left and right ear after challenge were significantly less in the compound THH group than those in the THH alone group (P
5.Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura.
Jing CUI ; Tie-nan ZHU ; Nong ZOU ; Miao CHEN ; Yong-qiang ZHAO
Acta Academiae Medicinae Sinicae 2013;35(1):116-120
OBJECTIVETo evaluate the efficacy and safety of rituximab in treating patients with refractory and/or relapsing thrombotic thrombocytopenic purpura (TTP).
METHODSTotally three patients received rituximab as salvage therapy in our hospital. Rituximab was administered at a weekly dose of 375 mg/m(2) for 2 or 4 consecutive weeks. After clinical remission, patients were followed up every 3 months.
RESULTSAll three patients achieved complete remission. The median time to platelet count recovery was 7 days (4-12 days) after the first rituximab infusion. During the follow-up (median: 12 months; range: 9-18 months), no patients experienced relapse. No side effect was noted during treatment and follow-up period.
CONCLUSIONTherapy with rituximab is effective and well tolerated for patients with refractory or relapsing TTP.
Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Female ; Humans ; Middle Aged ; Purpura, Thrombotic Thrombocytopenic ; drug therapy ; Retrospective Studies ; Rituximab ; Salvage Therapy ; Treatment Outcome
6.Clinical features of 76 Chinese patients with paroxysmal nocturnal haemoglobinuria.
Nong ZOU ; Bing HAN ; Hao CAI ; Ying XU ; Xuan WANG ; Rong-sheng LI ; Ti SHEN
Chinese Journal of Hematology 2012;33(6):471-474
OBJECTIVETo further analyse the relationship between the new technology and clinical characteristics in paroxysmal nocturnal haemoglobinuria (PNH) patients, and summarize the data of PNH during the past 15 years in China.
METHODS76 consecutive patients with PNH diagnosed in Peking Union Medical Colleague Hospital from 1997 - 2011 retrospectively.
RESULTSMost of the patients were diagnosed based on flow cytometric data. There were 46 male and 30 female patients. The median age at diagnosis was 40 (10 - 74). 46 (60.5%) patients presented with classical PNH, 16 (21.1%) pancytopenia, and 14 (18.4%) thrombosis. Anatomic locations of first thrombosis were intra abdominal in 7 patients, lower extremities in 3 patients, intracerebral in 2 patients, and pulmonary thrombosis in 2 patients. The size of PNH clone at first determination (shown by CD55 and CD59 negative percentage) was (61.23 ± 27.47)% and (60.24 ± 25.59)% on neutrophils; (34.24 ± 25.50)% and (32.22 ± 23.12)% on erythrocytes, respectively. The mean LDH level was (1199.2 ± 893.5) U/L. In our cohort, 13(17.0%) patients suffered from renal deficiency, 12 (15.8%) patients cholecystolithiasis, 10 (13.2%) patients hemorrhage and 9 (11.8%) patients infections. In a median of 7-year (range 0.5 - 20 years) follow-up (68 patients), 2 (2.9%) patients developed into myelodysplastic syndromes/ acute myeloid leukemia, 1(1.5%) patient ovary cancer, 11(14.5%) patients died. Patients with thrombosis had higher percentage of CD59 negative neutrophils \[(73.45 ± 22.32)%\] compared with those without thrombosis \[(58.3 ± 20.2)%\] (P < 0.05).
CONCLUSIONSThe cohort had higher percentage of classical hemolysis, thrombosis and renal dysfunction compared with previous reports in China. Patients with thrombotic events had higher percentages of CD55 and CD59 negative neutrophils.
Adolescent ; Adult ; Aged ; CD59 Antigens ; Child ; Erythrocytes ; Female ; Hemoglobinuria, Paroxysmal ; blood ; diagnosis ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Neutrophils ; Retrospective Studies ; Young Adult
7.An analysis of lung cancer mortality in China, 2004 - 2005.
Wan-qing CHEN ; Si-wei ZHANG ; Xiao-nong ZOU ; Ping ZHAO
Chinese Journal of Preventive Medicine 2010;44(5):378-382
OBJECTIVETo analyze the mortality distribution characteristics and epidemiological trend of lung cancer in 2004 - 2005 in China.
METHODSA total of 142 660 482 person years (72 970 241 person years in male, 69 690 241 person years in female) was covered in the Third National Retrospective Sampling Survey of Death Causes in China, 2004 - 2005. All death records of cancer of trachea, bronchus and lung were extracted. According to the different variations such as gender, urban or rural areas and three territory regions-Eastern, Central and Western China for lung cancer deaths, crude, age-adjusted, area-adjusted death rate, the constitute proportion to all cancer deaths, age-standardized death rate by Chinese standard population and by world standard population and rank of cancer-specific mortality were calculated. The statistic indexes of mortality were compared with that of previous retrospective death surveys in 1973 - 1975 and 1990 - 1992.
RESULTSIn the National Death Survey 2004 - 2005, there were 43 993 deaths caused by lung cancer with crude death rate of 30.84/100 000, age-standardized death rate by Chinese standard population of 20.24/100 000 and 27.62/100 000 by world standard population, accounted for 22.70% of total cancer deaths (193 841 cases). There were a total of 30 167 cancer deaths in male with crude death rate of 41.34/100 000 and 13 826 in female with crude death rate of 19.84/100 000. Lung cancer mortality was increased with age. In urban areas, the lung cancer was ranked the first cancer death causes with crude death rate of 40.98/100 000 (19 628/47 899 806), accounted for 27.29% of all cancer deaths. While in rural areas, the lung cancer was the second cancer death following liver cancer with crude death rate of 25.71/100 000 (24 365/94 760 676), accounted for 19.99% of all cancer deaths (121 905 cases). There were different death rates by different location division. Lung cancer crude death rate in east was the highest with rate of 37.85/100 000 (19 893/52 556 694) and in west was the lowest with rate of 21.76/100 000(8774/40 322 563). Crude death rate of lung cancer increased by 75.83% compared with the second survey (crude death rate was 17.54/100 000) in 1990 - 1992, increased by 464.84% compared with the first survey (crude death rate was 5.46/100 000) in 1973 - 1975, showing a significant uptrend.
CONCLUSIONLung cancer is the most important cancer affecting the health of Chinese urban residents. The mortality has been increasing significantly.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cause of Death ; Child ; Child, Preschool ; China ; epidemiology ; Death Certificates ; Female ; Health Surveys ; Humans ; Lung Neoplasms ; epidemiology ; mortality ; Male ; Middle Aged ; Young Adult
8.Analysis and prediction of breast cancer incidence trend in China.
Ni LI ; Rong-shou ZHENG ; Si-wei ZHANG ; Xiao-nong ZOU ; Hong-mei ZENG ; Zhen DAI ; Wan-qing CHEN
Chinese Journal of Preventive Medicine 2012;46(8):703-707
OBJECTIVEBased on the registered female breast cancer data from 1998 to 2007, to analyze the incidence of female breast cancer during the period and then to predict its trend from 2008 to 2015.
METHODSThe incidence data of breast cancer from 1998 to 2007 were sorted from National Cancer Registry Database, including 74 936 cases from urban areas and 8230 cases from rural areas, separately covering 164 830 893 and 55 395 229 person years. The crude incidence rates in urban and rural areas were calculated, and the age-standardized rate (ASR) was adjusted by World Segi's population composition. JoinPoint software was applied to analyze the 10 years' incidence trend and calculated the annual percentage of changing (APC), while Age-Period-Cohort Bayesian Model was used to fit the data and predict the incidence of breast cancer between 2008 and 2015.
RESULTSFrom 1998 to 2007, the incidence of breast cancer in the urban cancer registration areas was 45.46/100 000 (74 936/164 830 893), whose ASR was 31.28/100 000. While in rural registration areas, the incidence and ASR was 14.86/100 000 (8230/55 395 229) and 12.13/100 000. The breast cancer incidence in urban and rural areas separately rose from 36.17/100 000 (3920/10 838 355) and 10.39/100 000 (436/4 197 806) in 1998 to 51.24/100 000 (11 302/22 057 787) and 19.61/100 000 (1475/7 522 690) in 2007. During the 10 years, the breast cancer incidence increased both in urban and rural areas, but the increase rate in rural incidence (6.3%) was more significant than it in urban areas (3.9%). Age-Period-Cohort Bayesian Model predicted that the breast cancer incidence would increase to 53.87/100 000 (185 585 new cases) in urban areas and 40.14/100 000 (132 432 new cases) in rural areas, respectively.
CONCLUSIONThe breast cancer incidence has been increasing annually both in urban and rural areas in China; and an annually increase number of new cases have been predicted.
Breast Neoplasms ; epidemiology ; China ; epidemiology ; Female ; Humans ; Incidence ; Registries ; Rural Population ; Urban Population
9.Analysis and prediction of colorectal cancer incidence trend in China.
Zhen DAI ; Rong-shou ZHENG ; Xiao-nong ZOU ; Si-wei ZHANG ; Hong-mei ZENG ; Ni LI ; Wan-qing CHEN
Chinese Journal of Preventive Medicine 2012;46(7):598-603
OBJECTIVEBased on the data from National Cancer Registry between 1998 and 2007, to analyze the colorectal cancer incidence trend in China, and further to predict its incidence between 2008 and 2015.
METHODSWe picked up the incidence data of 111 281 cases of colorectal cancer in total from National Central Cancer Registry Database between 1998 and 2007, covering 446 734 668 person-year. The annual incidence rate of colorectal cancer both by area and gender were calculated; while the age standardized rate (ASR) was standardized by world's population age structure. The incidence trend was analyzed and the annual percentage change (APC) was calculated by JoinPoint software. Age-Period-Cohort Bayesian Model was applied to fit the colorectal cancer incidence trend in China between 1998 and 2007; and further to predict its incidence between 2008 and 2015.
RESULTSFrom 1998 to 2007, the colorectal cancer registered incidence was 24.91/100 000 (111 281/446 734 668), with the ASR at 17.67/100 000. The incidence in male population was 26.50/100 000 (60 015/226 508 545), with ASR at 19.90/100 000; and the incidence in female was 23.28/100 000 (51 266/220 226 123), with ASR at 15.73/100 000. In urban area, the male incidence rose from 23.29/100 000 (2617/11 237 967) in 1998 to 37.84/100 000 (8534/22 551 353) in 2007; while the female incidence increased from 21.75/100 000 (2357/10 838 355) to 31.34/100 000 (6913/22 057 787). And in rural areas, the male and female incidences rose from 10.36/100 000 (448/4 323 628) and 8.86/100 000 (372/4 197 806) in 1998 to 16.80/100 000 (1290/7 677 484) and 13.00/100 000 (978/7 522 690) in 2007 respectively. In this decade, the colorectal cancer incidence has increased both in urban and rural areas. In urban area, the male APC value was 5.5% and the female APC value was 4.0%; while in rural area, the male and female APC values were 6.0% and 4.3% respectively. After adjusted by age structure, the uptrend became gently; with the urban male and urban female APC values separately increased by 3.7%, 2.5% and 2.3%. The rural male APC value rocketed up by 8.4% after its inflection point in 2004. The Bayesian model predicted that the male and female colorectal cancer incidences would separately reach 33.92/100 000 (125 thousand cases) and 27.13/100 000 (93 thousand cases) in urban areas; and 13.61/100 000 (48 thousand cases) and 13.68/100 000 (45 thousand cases) in rural areas by year 2015.
CONCLUSIONThe colorectal cancer incidence in China has been increasing annually; and it will continue to rise in the next years.
Adult ; Aged ; Aged, 80 and over ; Bayes Theorem ; China ; epidemiology ; Colorectal Neoplasms ; epidemiology ; prevention & control ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Registries ; Rural Population ; Urban Population
10.Analysis and prediction of esophageal cancer incidence trend in China.
Hong-mei ZENG ; Rong-shou ZHENG ; Si-wei ZHANG ; Xiao-nong ZOU ; Ni LI ; Zhen DAI ; Wan-qing CHEN
Chinese Journal of Preventive Medicine 2012;46(7):593-597
OBJECTIVEBased on the registered esophageal cancer data from 1998 to 2007, to analyze the incidence of esophageal cancer during the period and then to predict its trend between year 2008 and 2015.
METHODSThe incidence data of esophageal cancer between 1998 and 2007 were sorted from National Cancer Registry Database. Data from forty selected registries were qualified and recruited in the study, including 86 427 cases in total, covering 446 734 668 person years. Crude incidence rates were calculated by area and gender. The standardized incidence rate was adjusted by World Segi's population composition. JoinPoint software was applied to analyze the 10 years' incidence trend and calculated the annual percentage change, while Age-Period-Cohort Bayesian Model was used to fit the data and predict the incidence between 2008 and 2015.
RESULTSBetween 1998 and 2007, the crude incidence rates among males and females in urban areas were separately 16.58/100 000 (28 207/170 131 309) and 7.14/100 000 (11 761/164 830 893), with standardized rates at 12.06/100 000 and 4.55/100 000, respectively. In rural areas, the crude incidence rates and the standardized rates were separately 51.98/100 000 (29 303/56 377 236) and 47.18/100 000 among males, and 30.97/100 000 (17 156/55 395 230) and 25.30/100 000 among females. During the ten years, the crude incidence trend of esophageal cancer among urban females decreased from 10.29/100 000 (1115/10 838 355) in 1998 to 6.29/100 000 (1387/22 057 787) in 2007. However, the crude incidence rate among rural males increased from 47.69/100 000 (2062/4 323 628) to 54.80/100 000 (4207/7 677 484) in the same period. And the rate among rural females and urban males did not change obviously. After adjusting population structure, in urban areas, the male incidence rate decreased by 2.1% annually and female incidence rate dropped by 7.5% annually. In rural areas, the female incidence rate fell by 1.3% annually, while the male incidence rate remained the same without significant changes. The prediction model estimated that there would be 134 474 new esophageal cancer cases diagnosed in year 2015, including 104 400 males and 30 074 females, while 52 506 cases came from urban areas and the other 81 968 cases were from rural areas.
CONCLUSIONThe esophageal cancer incidence showed a downtrend, especially among urban females. By year 2015, the threat of esophageal cancer will be alleviated.
Adult ; Aged ; Aged, 80 and over ; Bayes Theorem ; China ; epidemiology ; Esophageal Neoplasms ; epidemiology ; prevention & control ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Registries ; Rural Population ; Urban Population